Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director | June 16, 2021 | June 21, 2021 |
| BioAmber Inc.BIOA · Entity 167805 | Director | August 15, 2017 | August 16, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date June 16, 2021 · Filed June 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,125 |
Reported balance
After 2021-06-16 transaction · row 1
1 source rowRow 1 · 2021-06-16 · Grant · Acquired 4,172 · Balance 12,125 F1: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2022 annual meeting of the Company's stockholders or June 16, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2022 annual meeting of the Company's stockholders or June 16, 2022.
BioAmber Inc.
Report date August 15, 2017 · Filed August 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,833 |
Reported balance
After 2017-08-15 transaction · row 1
1 source rowRow 1 · 2017-08-15 · Purchase · Acquired 13,333 · Balance 14,833 F1: The fixed combination, consisting of one share of common stock and associated warrant to purchase one share of common stock was issued at a price of $0.75. |
| Common Stock Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2022-08-15 | Direct | 13,333 |
Reported balance
After 2017-08-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-08-15 · Purchase · Acquired 13,333 · Balance 13,333 F1: The fixed combination, consisting of one share of common stock and associated warrant to purchase one share of common stock was issued at a price of $0.75. |
Filing footnotes · ownership attribution and instrument terms
F1: The fixed combination, consisting of one share of common stock and associated warrant to purchase one share of common stock was issued at a price of $0.75.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2021 Filed Jun 21, 2021 20:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-004427 · ownership.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,125 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2022 annual meeting of the Company's stockholders or June 16, 2022. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 2,000 | $42.60 | $85,200.00 |
DisclosureSEC source: 0001171843-21-003534 · ownership.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,953 F1 · price: On May 12, 2021, Mr. Land sold 2,000 shares in multiple trades ranging from $42.50 to $42.72. The price reported above reflects the weighted average sales price. Mr. Land undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:08 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 3,446 | $36.77 | $126,709.42 |
DisclosureSEC source: 0001171843-20-007934 · ownership.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,953 F1 · security: On November 10, 2020, Mr. Land sold 3,446 shares in multiple trades ranging from $36.71 to $36.98. The price reported above reflects the weighted average sales price. Mr. Land undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 23:54 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 2,700 | $42.68 | $115,236.00 |
DisclosureSEC source: 0001171843-20-001364 · ownership.xml · nonDerivative · entry 2 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,399 F2 · security: On February 26, 2020, Mr. Land sold 2,700 shares in multiple trades ranging from $42.53 to $42.80. The price reported above reflects the weighted average sales price. Mr. Land undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:54 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001364 · ownership.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,099 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 25, 2021. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 20:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 3,000 | $55.44 | $166,320.00 |
DisclosureSEC source: 0001171843-19-004979 · ownership.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,992 F1 · shares: On July 29, 2019, Mr. Land sold 3,000 shares in accordance with a previously-executed 10b5-1 Sales Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:34 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 4,000 | $33.06 | $132,240.00 |
DisclosureSEC source: 0001171843-19-001389 · ownership.xml · nonDerivative · entry 2 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,992 F2 · price: On February 26, 2019, Mr. Land sold 4,000 shares in multiple trades ranging from $32.76 to $33.13. The price reported above reflects the weighted average sales price. Mr. Land undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:34 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001389 · ownership.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,992 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:08 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000693 · formfour.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,150 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 24, 2019. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 13:37 UTC | BioAmber Inc. BIOA · Entity 167805 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 13,333 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001209191-17-049132 · doc4.xml · derivative · entry 2 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2022-08-15 F1 · price: The fixed combination, consisting of one share of common stock and associated warrant to purchase one share of common stock was issued at a price of $0.75. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 13:37 UTC | BioAmber Inc. BIOA · Entity 167805 | PurchaseCommon Stock | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-049132 · doc4.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,833 F1 · price: The fixed combination, consisting of one share of common stock and associated warrant to purchase one share of common stock was issued at a price of $0.75. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 13:32 UTC | BioAmber Inc. BIOA · Entity 167805 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 40,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001209191-17-049131 · doc4.xml · derivative · entry 2 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2022-08-15 F1 · price: The fixed combination, consisting of one share of common stock and associated warrant to purchase one share of common stock was issued at a price of $0.75. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 13:32 UTC | BioAmber Inc. BIOA · Entity 167805 | PurchaseCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-049131 · doc4.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The fixed combination, consisting of one share of common stock and associated warrant to purchase one share of common stock was issued at a price of $0.75. Read SEC document |
| May 11, 2017 Filed May 17, 2017 17:55 UTC | BioAmber Inc. BIOA · Entity 167805 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-17-033326 · doc4.xml · derivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-05-11 F1 · derivative.exercise_date: These options will vest on a quarterly basis, as follows: 25% will vest on August 11, 2017, 25% will vest on November 11, 2017, 25% will vest on February 11, 2018 and 25% will vest on May 11, 2018. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 2,635 | $49.08 | $129,325.80 |
DisclosureSEC source: 0001171843-17-001109 · f4_land022417.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,524 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:08 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 1,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-000588 · formfour.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,159 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.